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ABSTRACT
The objective of this study was to examine the effect of (-)-epigallocatechin-3-gallate (EGCG) on cyclooxygenase 2 (COX-2)
and matrix metalloproteinase (MMP) 3, 9, and 13 expressions induced by IL-1b in rat meniscal fibrochondrocytes. Rat normal
meniscal fibrochondrocytes were enzymatically isolated from meniscal tissue from the hind leg knee joint. Cells were pretreated
with EGCG at a concentration of 50 mM to examine its effect in the presence of IL-1b insult. Reverse transcriptase-polymerase
chain reaction (RT-PCR) and real-time PCR were used to assess the COX-2 and MMP3, 9, and 13 gene expressions, respectively.
COX-2 gene upregulation induced by IL-1b in primary cultures of rat meniscal fibrochondrocytes was significantly suppressed by
EGCG (p < 0.05). MMP 3, 9, and 13 gene expressions were also significantly induced by IL-1b stimulation and significantly inhibited by EGCG treatment (p < 0.05). These results indicated that EGCG may be of value in the treatment of meniscal inflammation
associated with IL-1b secretion.
Key words: epigallocatechin-3-gallate, cyclooxygenase 2, matrix metalloproteinase, meniscus, fibrochondrocyte, IL-1b

INTRODUCTION
The knee joint menisci are able to distribute loads to
maintain joint stabilization and lubrication(1). However,
they are frequently injured during trauma, which is characterized by the occurrence of tears and/or ragged or
peripheral serrated splitting(2,3). Also, degenerative tears
can commonly occur in older persons and in association with osteoarthritis (OA) of the knee. It has been well
recognized that high interleukin-1 beta (IL-1b) expression is present on the surface of osteoarthritic cartilage
and synovial membranes at all stages of the disease (46)
. Expression of IL-1b may lead to induction of cyclooxygenase 2 (COX-2) and subsequent prostaglandin E2
(PGE2) production, which may subsequently modulate
matrix degradation of the human knee joint cartilage (7).
Matrix metalloproteinases (MMPs) are a large
family of zinc-dependent proteinases involved in the
degradation and remodeling of the extracellular matrix.
Under normal physiological conditions, the activities
of these enzymes are involved in normal cell functions
* Author for correspondence. Tel: +886-4-26562951;
Fax: +886-4-26584951; E-mail: tsao0425@yahoo.com.tw

and regulate host defense mechanisms. These enzymes
are tightly regulated by endogenous tissue inhibitors of
metalloproteinases (TIMPs)(8).MMPs have also been
reported to be associated with tumorigenic processes
that promote tumor invasion and metastasis (9). Aberrant MMP activities due to an imbalance in the levels of
MMPs and TIMPs have been implicated in the pathogenesis of a variety of diseases such as OA and rheumatoid
arthritis (RA)(10). Early work has demonstrated the presence of multiple MMP family members in disease-state
joints, and recent advances in the development of new
knockout mice and disease models have allowed investigators to directly test their roles in arthritis (11).
MMPs have been found to be elevated in animal
models and in cartilage tissue and synovial fluid from OA
and RA patients. MMP-3 and MMP-9 are initially upregulated in the synovium, which may play a pivotal role in
the pathogenesis of cartilage degeneration (12-14). MMP13
catalyzes the cleavage of type II collagen, the main
structural protein in articular hyaline cartilage (15), and
this is the rate-limiting step in the process of collagen
degradation.
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MMP inhibitors (MMPIs) are expected to be useful
for the treatment of diseases such as OA, RA, and
cancer. A vast number of molecules such as doxycycline, CMT-7 (a modified tetracycline), and Ro 32-3555
have been developed as MMPIs in recent years (16,17).
The (-)-Epigallocatechin-3-gallate (EGCG) is extracted
from the leaves of the Camellia sinensis plant as its most
abundant catechin, and the beneficial effects of this purified compound have been tested in various diseases.
EGCG may prevent UVB-induced skin damage, isoproterenol-induced myocardial infarction, and lipopolysaccharide-induced oxidative stress by its function as an
antioxidant (18-20). EGCG also inhibits the proliferation
of human prostate and breast cancer cells (21,22). EGCG
has been shown to inhibit the IL-1b-induced expression
and activity of cyclooxygenase 2 (COX-2) and inducible
nitric oxide synthase (iNOS) in OA chondrocytes isolated
from degenerated hyaline cartilage (23). Its effects on
other arthritic conditions have also been examined (24,25).
However, its effect on meniscal fibrochondrocytes has
not yet been investigated.
In the present study we established primary cultures
of meniscal fibrochondrocytes and examined their
responses to IL-1b insult (26,27). We then tested the effect
of EGCG on MMP3, 9, and 13 gene expressions induced
by IL-1b. EGCG demonstrated an inhibitory effect on
COX-2 and MMP3, 9, and 13 gene expressions. These
data suggest that EGCG may be of value in the treatment
of meniscal inflammation associated with IL-1b secretion.

MATERIALS AND METHODS
I. Materials
The (-)-Epigallocatechin gallate (EGCG) was
purchased from Sigma-Aldrich, Inc. (St. Louis, MO,
USA). A stock solution at a concentration of 10 mM
was prepared in deionized water (50 mg of EGCG
powder in 10.9 mL of water). IL-1b, a powder product,
was purchased from R&D Company (Minneapolis, MN,
USA). An IL-1b stock solution at a concentration of 5 mg/
mL was prepared in sterile phosphate-buffered saline
(PBS).
II. Meniscal Fibrochondrocytes Isolation and Culture
Male Sprague Dawley (SD) rats (8-week-old,
280-300 g) were obtained from BioLASCO Taiwan Co.,
Ltd (Taiwan). All experiments were approved by the
local Institutional Review Board and performed in adherence to the Laboratory Animals Guidelines (Council of
Agriculture, Executive Yuan, R.O.C.) for the treatment
of laboratory animals. Meniscus tissue is fibrocartilage
and predominantly contains fibrochondrocytes and a
few small, peripheral blood vessels. The inner third of
the meniscus tissue is devoid of blood vessels. The inner

third of the meniscus tissue was aseptically removed
from normal SD rats, cut into small fragments, and incubated with antimicrobial solution (500 IU/mL penicillin/
streptomycin, Gibco™ Invitrogen, Burlington, Canada)
for 1 h and then washed with PBS before digestion with
3 mg/mL type H collagenase (Sigma, St. Louis, MO,
USA) at 37°C for 12 h. The samples were checked for
digestion by examination under a light microscope. The
cell suspension was collected using a sterile pastette.
After centrifugation at 1500 rpm for 10 min, the supernatant was discarded and the pellet resuspended in 10
mL DMEM-F12 medium supplemented with 10% FBS
(Sigma, St. Louis, MO, USA), 100 IU/mL penicillin
(Gibco), and 100 mg/mL streptomycin (Gibco). Cells were
seeded in a complete medium at a density of 1 × 105 cell/
mL in 60 mm petri dishes (Orange Scientific, BraineI’Alleud, Belgium) and then cultured in a humidified 5%
CO2 atmosphere at 37°C. Cells between passages 2 and 3
were used.
III. Experimental Protocol for EGCG Test
Cells were cultured for 2 weeks in 60 mm tissue
culture Petri dishes. Dishes of meniscal fibrochondrocytes were placed in serum-free media overnight, then
incubated with 10 ng/mL of IL-1b at 37°C for 0 (control)
and 6 h. Cells were pretreated with EGCG for 12 h at a
concentration of 50 mM, as described previously for RA
synovial fibroblasts (28).
IV. Immunocytochemistry
After a 24 h culture of meniscal fibrochondrocytes, cells on the dish were washed with ice-cold PBS
twice and then fixed using 2 mL of a 1: 1 methanol/
acetone mixture per dish for 5 min at -20°C. Cells were
then stained by immunocytochemistry. Immunodetection for CD34 and type II collagen was performed with
a standard avidin-biotin-peroxidase complex detection
kit (DakoCytomation, Glostrup, Denmark). Dishes were
washed twice with PBS and blocked by incubation with
200 mL 1% non-immune horse serum (Vector Laboratories Inc., Burlingame, California, USA) in 1% BSA in
antibody diluent (DakoCytomation) for 30 min at room
temperature. The solution was poured off and the cells
incubated sequentially with CD34 (1: 100) (DakoCytomation, Germany) and type II collagen (1: 200) specific
antibody (Sigma) for 60 min, biotinylated secondary
antibody (1: 200) for 45 min, and HRP-conjugated streptavidin for 20 min. Between each incubation cells were
washed with TBST (12.5 mM Tris/HCl, pH 7.6, 137
mM NaCl, 0.1% Tween 20) three times. For the negative
controls, the primary antibody was omitted. The chromogen 3-amino-9-ethylcarbazole (AEC) was then added
for 15 min, and then the cells were counterstained with
Mayer’s hematoxylin. The cells were mounted with a
cover slip and visualized under a light microscope.
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V. Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated from cells using an easyBLUETM Total RNA Extraction Kit (iNtRON, Biotechnology, Gyeonggi-do, Korea). For first strand cDNA
synthesis, 3 mg of total RNA was used in a single-round
RT reaction (total volume 20 mL) containing 0.75 mg
oligo(dT)14 primer, 1 mM dNTPs, 1x first strand buffer,
0.4 mM DTT, 40 units RNaseOut recombinant ribonuclease inhibitor, and 200 units of superscript II
reverse transcriptase (Invitrogen). The RT reaction was
performed at 42°C for 2 h, followed by 95°C for 5 min.
The PCR was run using 0.9 mL of the RT reaction mixture
as template, 0.4 mM of gene specific primers, 1x PCR
buffer, 0.25 mM dNTPs, and 1.5 units of Taq DNA polymerase (BioMan, Taipei, Taiwan). The amplification was
carried out at 94°C for 2 min, then for 35 cycles at 94°C
for 45 sec, 56°C for 1 min, and 72°C for 45 sec followed
by a final extension at 72°C for 10 min. The PCR products were size-fractionated by 1.5% agarose gel electrophoresis, and DNA bands were visualized by staining the
gel with 0.1 mg/mL ethidium bromide. The bands were
analyzed using a gel documentation system (Bio-Profil,
Bio-1D version 99, Viogene, CA, USA). The primers
used were as follows: COX-2 5’-GTCTCTCATCTGCAATAATGTG-3’ (sense) and 5’-ATCTGTGTGGGTACAAATTTG-3’ (antisense) (Gene bank accession number
S67722.1; PCR product 801 bp); GAPDH 5’-CCCATCACCATCTTCCAGGAG-3’ (sense) and 5’-GTTGTCATGGATGACCTTGGCC-3’ (antisense) (Gene bank accession
number X02231; PCR product 284 bp).

(Table 1). Two microliters of template cDNA was amplified with SYBR Green Supermix (Biorad Hercules,
CA, USA) in a 25 mL reaction containing SYBR Green
Supermix, 0.3 mM of each primer, and de-ionized water.
The mixture was initially heated at 95°C for 3 min,
followed by 40 cycles of denaturation at 95°C for 30 sec,
annealing at 55°C for 45 sec, and extension at 72°C for
10 sec. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal
control. Following amplification, melt curve protocols
were performed to ensure that primer-dimers or nonspecific products had been eliminated or minimized. To
analyze the data obtained by real-time PCR, the comparative threshold cycle (CT ) method was applied. Briefly,
the amount of a target, normalized to GAPDH and relative to a calibrator, is determined by 2-∆∆CT, where ∆∆CT
﹦∆ CT (sample) – ∆ CT (calibrator), and ∆ CT is the CT of
the target gene subtracted from the CT of GAPDH(29).
VII. Statistical Analysis
The values from RT-PCR were expressed as the ratio
of the band intensity of the target gene to glyceraldehyde3-phosphate dehydrogenase (GAPDH). Variance and p
values were analyzed by Alphaimager 1220 V5.5 (Alpha
Innotech Corporation, San Leandro, CA, USA). Student’s
test was used for statistical comparison between groups.
The results were considered significant at a value of
p < 0.05.

RESULTS

VI. Real-time Quantitative PCR

I. Characterization of Meniscal Fibrochondrocytes

In order to quantitatively analyze the regulatory effects of IL-1b and/or EGCG on the expression of
MMP3, 9, and 13 in meniscal fibrochondrocytes, realtime RT-PCR was performed using a Biorad iCycler iQ
(Biorad, Hercules, CA, USA) utilizing specific primers

Although the meniscal fibrochondrocytes were
isolated from the inner third of the meniscus tissue,
the isolated tissues were further characterized to make
sure they contained no other cellular components.
The cultured meniscus cells were characterized by

Table 1. Oligonucleotides primers for real-time quantitative PCR
Gene
MMP3

MMP9

MMP13

GAPDH

Sequence (5’-3’)
Forward: TGGGAAGCCAGTGGAAATG
Reverse: CCATGCAATGGGTAGGATGAG
Forward: TGCTCCTGGCTCTAGGCTAC
Reverse: TTGGAGGTTTTCAGGTCTCG
Forward: CTGACC TGG GATTTCCAAAA
Reverse: ACACGTGGTTCCCTGAGAAG
Forward: CTCAACTACATGGTCTACATGTTCCA
Reverse: CTTCCCATTCTCAGCCTTGACT

Size (bp)

Accession no.

81

NM_133523

88

NM_031055

90

XM_343345

81

X02231
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Figure 1. Meniscal fibrochondrocytes was characterized by immunocytochemistry.
(A) Negative control with omitted primary antibody showed no signal. (B) Primary cultures of meniscus cells demonstrated expression of
type II collagen. (C) The fibrochondrocytes did not express CD34 (200x). Scale bar 20 mm.

immunocytochemistry with antibodies to detect the
expression of type II collagen (produced by fibrochondrocytes) and CD34 (endothelial cell marker expressed
by blood vessels). Meniscus cells in vitro (100%)
demonstrated a polygonal shape and expression of type
II collagen. The cultured cells did not express CD34
(Figure 1A, 1B and 1C). The miniscal fibrochondrocytes
were then used for the following experiments.

Cyclooxygenase 2 induction by IL-1b in meniscus
chondrocytes was examined, and then the effect of
EGCG at a concentration of 50 mM was investigated.
The concentration of EGCG used showed no significant
effect on cell viability. IL-1b at a concentration of 10 ng/
mL significantly induced COX-2 gene expression. The
ratio of COX-2 / GAPDH was control 0.0972 ± 0.0433
versus IL-1b stimulation 0.6920 ± 0.1103 (p = 0.00828).
Induction of COX-2 was significantly inhibited by pretreatment with EGCG (COX-2 / GAPDH: 0.1012 ± 0.0315,
p = 0.04079). Treatment with EGCG alone showed no
significant change in COX-2 gene expression (COX-2
/ GAPDH: 0.0192 ± 0.09807, p = 0.09807) (Figure 2).
These data suggested that EGCG could suppress the
COX-2 expression inducted by IL-1b stimulation in
meniscal fibrochondrocytes.
III. Inhibition of MMP3, 9, and 13 Expression by EGCG
Six normal rat meniscal fibrochondrocytes were
isolated and cultured. IL-1b significantly induced
MMP3, 9, and 13 gene expressions in meniscal fibrochondrocytes. The increases were 102.4 ± 28.7 (p =
0.00586), 156.9 ± 89.2 (p = 0.01739), and 144.2 ± 57.6 fold
(p = 0.00511) for MMP3, MMP9, and MMP13, respectively. The upregulations of MMP3, 9, and 13 were
significantly inhibited by EGCG. Treatment with EGCG
alone did not significantly cause any change in MMP 3, 9,
and 13 expressions as compared with the control (Figure
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Figure 2. COX-2 induction by IL-1b was suppressed by EGCG at a
concentration of 50 mM (EGCG50). COX-2 expression by meniscal
fibrochondrocytes was assessed after 6 h co-culture of cells with
IL-1b at a concentration of 10 ng/mL. Upper panel: a representative
agarose gel demonstrated COX-2 mRNA expression as assessed
by reverse transcription-polymerase chain reaction (RT-PCR).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as
internal control. Lower panel: the graph showed the results of densitometric analysis of DNA bands expressed as the mean ± standard
deviation (S.D.) of the COX-2 / GAPDH ratio (n = 6). *,#p < 0.05.

3A, 3B, and 3C). These data suggested that EGCG could
suppress MMP 3, 9, and 13 expressions induced by IL-1b
stimulation in meniscal fibrochondrocytes.

DISUSSION
The present study has demonstrated that COX-2 and
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Figure 3. Expression of M M P3, 9, and 13 i nduced by I L -1b
stimulation was suppressed by EGCG at a concentration of 50
mM (EGCG50). MMP3 (A), MMP9 (B), and MMP13 (C) were
significantly induced by IL-1b and suppressed by EGCG (n = 6). *,#p
< 0.05.

MMP3, 9, and 13 gene expressions are induced by IL-1b
stimulation. This upregulation is suppressed by pretreatment with EGCG in meniscal fibrochondrocytes. The
high levels of cyclooxygenase / prostaglandin E synthase

(COX / PGES) activity in IL-1b-treated meniscus
explanted from osteoarthritic patients have been demonstrated(30). Consistent with our data, IL-1b can induce
COX-2 expression in normal meniscal fibrochondrocytes in vitro. After establishment of this in vitro model
we examined the effect of EGCG on the gene expression of the matrix degradation enzymes, MMP3, 9, and
13, which are involved in the pathogenesis of meniscus
degeneration.
MMP may be involved in cancer invasion and
metastasis(31,32). EGCG, a green tea polyphenol with
chemopreventive properties, has been shown to be an
inhibitor of MMPs in human colorectal cancer cells (33),
bronchus tumor cells (34), and oral cancer cells(35).
The inhibition pathway of MMP2 and MMP9 in prostate tumor cells by EGCG is mediated via inhibition of
phosphorylation of the extracellular regulated kinase
(ERK1/2) and p38 molecules, and inhibition of activation
of transcription factors c-jun and nuclear factor-kappa
B (NF-kB)(36). In addition to the above anti-neoplastic
effects, EGCG also shows benefits in other systems.
EGCG suppresses MMP9 activation and reduces
neuronal death after transient global cerebral ischemia
in the mouse brain(37). EGCG can rapidly and substantially hamper UV-B irradiation - induced activation of
extracellular matrix degradation(38,39). EGCG reduces
the IL-1b stimulated expression of both collagenase and
stromelysin, an effect which may be mediated by inhibition of the JNK/SAPK pathway in human tendon fibroblasts(40). EGCG markedly attenuates the activation of
hepatic stellate cells, as well as their MMP2 activity, to
prevent hepatic fibrosis (41,42).
In the articular systems, the effects of EGCG on RA
synovial fibroblasts and OA articular chondrocytes from
hyaline cartilage have also been tested. In synovial fibroblasts, EGCG suppresses TNF-α - induced production
of MMP1 and MMP3, which is accompanied by inhibition of the mitogen activated protein kinase (MAPK)
and activator protein-1 (AP-1) pathways (43). EGCG may
cause a complete block of IL-1b - induced production of
RANTES, ENA-78, and GRO-α (28). In articular chondrocytes, EGCG inhibits the IL-1b induced mRNA and
protein expression of MMP1 and MMP13(44). The effect
of EGCG on MMP gene suppression is consistent with
our model. Nevertheless, MMP3, 9, and 13 are involved
in meniscal fibrochondrocytes. Inhibition of MMP by the
broad-spectrum MMP inhibitor, GM6001, can enhance
in vitro repair of the meniscus (45). EGCG has demonstrated its effects in the modulation of MMP activity,
including the neoplastic systems, non-neoplastic systems,
and arthritic systems. In our meniscus models, we also
identify for the first time that IL-1b induces MMP3, 9, 13
upregulations in rat normal meniscus cells and this MMP
upregulation was also inhibited by EGCG. EGCG may be
of value in the treatment of arthritis. The detailed mechanisms and signalling pathways involved in this process
need to be further elucidated.
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